

Hans-Jochem Kolb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7920988/publications.pdf>

Version: 2024-02-01

29
papers

1,051
citations

759233

12
h-index

794594

19
g-index

29
all docs

29
docs citations

29
times ranked

1326
citing authors

#	ARTICLE	IF	CITATIONS
1	The FLAMSA concept – past and future. <i>Annals of Hematology</i> , 2020, 99, 1979-1988.	1.8	10
2	European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. <i>Leukemia</i> , 2019, 33, 508-517.	7.2	45
3	Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies. <i>Stem Cells International</i> , 2019, 2019, 1-12.	2.5	19
4	As Time Goes by –. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1-2.	2.0	10
5	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. <i>Haematologica</i> , 2013, 98, 518-525.	3.5	31
6	Stem cell transplants for patients with relapsed/refractory leukaemia. <i>Current Opinion in Hematology</i> , 2009, 16, 444-452.	2.5	7
7	Influence of Polymorphism within the Heme Oxygenase-I Promoter on Overall Survival and Transplantation-Related Mortality after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1180-1189.	2.0	13
8	Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , 2008, 112, 1971-1971.	1.4	10
9	Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation – Follow up. <i>Blood</i> , 2008, 112, 453-453.	1.4	1
10	Factors Determining Survival after Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 564-564.	1.4	0
11	Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML.. <i>Blood</i> , 2008, 112, 2142-2142.	1.4	1
12	Allogeneic Stem Cell Transplantation with Dose-Reduced Conditioning in Relapsed Follicular and Mantle Cell Lymphoma - A Prospective Phase II Trial of the German Low Grade Lymphoma Study Group (GLSG).. <i>Blood</i> , 2007, 110, 3058-3058.	1.4	1
13	Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.. <i>Blood</i> , 2007, 110, 1651-1651.	1.4	0
14	Immune Effects of Imatinib in Chronic Myelogenous Leukemia In Vitro.. <i>Blood</i> , 2007, 110, 2956-2956.	1.4	0
15	Adoptive Immunotherapy: Guidelines and Clinical Practice. , 2006, , 221-231.		0
16	Allogeneic Rejection of High Grade Lymphoma: Evidence for Immune Escape in a Haploidentical Murine Model.. <i>Blood</i> , 2006, 108, 3171-3171.	1.4	0
17	Polymorphism in the Promoter Region of the Hemeoxygenase I Gene of the Donor Influences Overall Survival and Graft Versus Host Disease.. <i>Blood</i> , 2006, 108, 2879-2879.	1.4	0
18	Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5675-5687.	1.6	378

#	ARTICLE	IF	CITATIONS
19	Adoptive Immunotherapy of p53-Mutated B-CLL with a Trifunctional Antibody (Anti-CD3 x Anti-CD20) and Allogeneic Donor Lymphocyte Transfusion.. Blood, 2005, 106, 4823-4823.	1.4	0
20	Rejection of Primary Lymphoma Cells Derived from c-myc-Transgenic Mice after Haploidentical Transplantation: Treatment of the Tumor May Confer to Resistance Against GvL-Effect.. Blood, 2005, 106, 5243-5243.	1.4	0
21	In-vivo generation of leukaemia-derived dendritic cells. Best Practice and Research in Clinical Haematology, 2004, 17, 439-451.	1.7	15
22	Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Current Opinion in Oncology, 2004, 16, 167-173.	2.4	32
23	Graft-versus-leukemia reactions in allogeneic chimeras. Blood, 2004, 103, 767-776.	1.4	370
24	In-vivo generation of leukaemia-derived dendritic cells. Best Practice and Research in Clinical Haematology, 2004, 17, 439-451.	1.7	8
25	A Comparison of Acute GVHD after HLA-Haploidentical and HLA-Identical Stem Cell Transplantation.. Blood, 2004, 104, 2151-2151.	1.4	0
26	Adoptive Immunotherapy in Chimeras with Donor Lymphocytes. Acta Haematologica, 2003, 110, 110-120.	1.4	20
27	Tolerance and chimerism1. Transplantation, 2003, 75, 26S-31S.	1.0	18
28	Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. British Journal of Haematology, 2000, 111, 596-607.	2.5	50
29	Prevention of graft-versus-host disease in DLA-haplotype mismatched dogs and hemopoietic engraftment of CD6-depleted marrow with and without cG-CSF treatment after transplantation. Tissue Antigens, 1994, 43, 170-178.	1.0	12